The drug will be sold under the brand name Dynulta
Emcure Pharmaceuticals has launched India’s first generic version of sucroferric oxyhydroxide for the control of increased serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The drug will be sold under the brand name Dynulta. Its active component is sucroferric oxyhydroxide developed indigenously by Emcure.
Dynulta will be manufactured at Emcure’s state-of-the-art plant at Jammu and will be marketed at less than 70 per cent cost of the innovator brand.
“The incidence of CKD is on the rise in India. Dynulta will provide an efficacious and cost-effective remedy for Indian patients” said Namita Thapar, Executive Director, Emcure Pharmaceuticals.
Sucroferric oxyhydroxide displays a high phosphate binding capacity, resulting in effective serum phosphorus control. This was demonstrated in a phase III study of sucroferric oxyhydroxide versus sevelamer. Real-world studies show that patients who switch to sucroferric oxyhydroxide from another phosphate binder achieve better long-term serum phosphorus control with a lower number of pills. A lower pill burden can translate into better patient compliance with treatment. Studies have shown that sucroferric oxyhydroxide is effective in the reduction of serum phosphorus in a broad range of dialysis patients.
The innovator company for sucroferric oxyhydroxide is Vifor Fresenius Medical Care Renal Pharma, a joint operation between Vifor Pharma and Fresenius Medical care, providers of dialysis services. It is marketed internationally as Velphoro, which is not available in India.